Merck is pleased to provide you with a downloadable voucher for a free trial of MAXALT or MAXALT-MLT for your patients with migraine.
Merck would like your patients with migraine to experience the benefits of MAXALT or MAXALT-MLT. For your patients to receive a free trial for 3 tablets of MAXALT or 3 orally disintegrating tablets of MAXALT-MLT, please follow the instructions below:
To initiate a free trial for an appropriate patient, you should:- Write a prescription for up to 3 tablets of MAXALT or 3 orally disintegrating tablets of MAXALT-MLT. No substitutions are permitted.
- Before prescribing MAXALT or MAXALT-MLT, please read the accompanying Prescribing Information.
- Refills are not required and there are no requirements to purchase any product or service to use the voucher. If you want your patient to continue taking MAXALT or MAXALT-MLT beyond the free trial period, please write a separate prescription based on your recommended therapy.
- Give the valid signed prescription and the voucher to the patient.
- Eligible patients can take the voucher and the prescription to any participating eligible retail pharmacy to receive their free trial.
- For additional copies of the Prescribing Information, call 800-672-6372, visit maxalt.com, or contact your Merck representative.
- The voucher is valid for one free trial of MAXALT or MAXALT-MLT.
- Limit 1 voucher per patient for the duration of the program.
- Valid for 1-time use only. Free trial offer valid only for up to 3 tablets of MAXALT or 3 orally disintegrating tablets of MAXALT-MLT. No purchase is necessary. Refills are not required.
- The voucher is not transferable. No substitutions are permitted. Cannot be combined with any other free trial, coupon, discount, prescription savings card, or other offer.
- The voucher is not insurance.
- You must be 18 years of age or older to redeem the voucher. Patient and prescriber agree not to seek reimbursement for all or any part of the benefit received through this offer. The free trial of MAXALT cannot be used toward any out-of-pocket costs under any plan (such as true out-of-pocket expense [TrOOP]).
- The voucher can be used only by eligible US residents at participating eligible retail pharmacies in the United States. Product must originate in the United States.
- The voucher is property of Merck and must be turned in on request.
- Merck reserves the right to rescind, revoke, or amend this offer at any time without notice.
- It is illegal to sell, purchase, trade, or counterfeit the voucher. Void if reproduced. Void where prohibited by law, taxed, or restricted.
- Please read the accompanying Patient Product Information and discuss it with your doctor. Also accompanying is the physician Prescribing Information.
- Expiration Date: 06/30/2011.
Phenylketonurics: MAXALT-MLT contains phenylalanine.
MAXALT is indicated for the acute treatment of migraine attacks with or without aura in adults. MAXALT is not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine. Safety and effectiveness of MAXALT have not been established for cluster headache, which is present in an older, predominantly male population.
Selected Safety InformationMAXALT should not be given to patients with ischemic heart disease (eg, angina pectoris, history of myocardial infarction, or documented silent ischemia) or to patients who have symptoms or findings consistent with ischemic heart disease, coronary artery vasospasm, including Prinzmetal’s variant angina, or other significant underlying cardiovascular disease. Because MAXALT may increase blood pressure, it should not be given to patients with uncontrolled hypertension. MAXALT should not be used within 24 hours of treatment with another 5-HT1 agonist, or an ergotamine-containing or ergot-type medication like dihydroergotamine or methysergide. MAXALT should not be administered to patients with hemiplegic or basilar migraine. Concurrent administration of MAO inhibitors or use of rizatriptan within 2 weeks of discontinuation of MAO inhibitor therapy is contraindicated. MAXALT is contraindicated in patients who are hypersensitive to rizatriptan or any of its inactive ingredients.
MAXALT should only be used where a clear diagnosis of migraine has been established.
MAXALT can cause coronary vasospasm and should not be given to patients with documented ischemic or vasospastic coronary artery disease (CAD). It is strongly recommended that MAXALT not be given to patients in whom unrecognized CAD is predicted by the presence of risk factors unless a cardiovascular evaluation provides satisfactory clinical evidence that the patient is reasonably free of CAD and ischemic myocardial disease or other significant underlying cardiovascular disease. For patients with these risk factors who are determined to have a satisfactory cardiovascular evaluation, see WARNING section of the Prescribing Information.
Serious adverse cardiac events, including acute myocardial infarction, have been reported within a few hours following the administration of rizatriptan. Life-threatening disturbances of cardiac rhythm and death have been reported within a few hours following the administration of other 5-HT1 agonists. Considering the extent of use of 5-HT1 agonists in patients with migraine, the incidence of these events is extremely low.
Cases of life-threatening serotonin syndrome have been reported during combined use of selective serotonin reuptake inhibitors (SSRIs) or serotonin norepinephrine reuptake inhibitors (SNRIs) and triptans.
The most common adverse events include asthenia/fatigue, somnolence, pain/pressure sensations, and dizziness, and they appear to be dose related. Potentially important adverse events that have occurred in clinical practice and reported through postmarketing surveillance include myocardial ischemia, myocardial infarction, peripheral vascular ischemia, stroke, serotonin syndrome, seizure, dysgeusia, hypersensitivity reaction, anaphylaxis/anaphylactoid reaction, angioedema (eg, facial edema, tongue swelling, pharyngeal edema), wheezing, and toxic epidermal necrolysis.
Before prescribing MAXALT-MLT or MAXALT, please read the Prescribing Information.
To print a free trial voucher for MAXALT or MAXALT-MLT, click on the button below.
DO NOT CLOSE THIS WINDOW AFTER CLICKING THE PRINT BUTTON. The window closes automatically.
Be sure to check that each printed voucher contains an ID number (vouchers with an "XXXXX" are not valid).
Only the original voucher is valid and redeemable at the pharmacy.
The voucher offer may only be redeemed once.
The voucher is subject to the limitations, please see terms and conditions on the voucher.
Voucher expires 06/30/2011.
Each voucher offer may only be redeemed once per patient.
This site is intended only for health care professionals of the United States, its territories, and Puerto Rico.
| For general health information | ||
 |
 |
 |
MAXALT, MAXALT-MLT, MerckMedicus, MerckSource and MerckServices are registered trademarks of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
PRIVACY POLICY